308 Sabcs PPTs View free & download

A critique of SABCs political coverage. PowerPoint PPT Presentation

A critique of SABCs political coverage. - Opportunities that the current political climate offers developmental journalism ... Not restricting access to news sources. ... a plurality of views and news. ...

Opportunities that the current political climate offers developmental journalism ... Not restricting access to news sources. ... a plurality of views and news. ...

| PowerPoint PPT presentation | free to download

SABCs Funding Model Options for the Future PowerPoint PPT Presentation

SABCs Funding Model Options for the Future - 1. SABC's Funding Model Options for the Future. Justine Limpitlaw. Media ... controversial, devil's advocate, puts the cat among the pigeons, stir debate etc ...

1. SABC's Funding Model Options for the Future. Justine Limpitlaw. Media ... controversial, devil's advocate, puts the cat among the pigeons, stir debate etc ...

| PowerPoint PPT presentation | free to view

The SABCs legal structure the benefits disadvantages of a national versus a regional structure PowerPoint PPT Presentation

The SABCs legal structure the benefits disadvantages of a national versus a regional structure - ... within the governance itself, politics will find a way to ... Presidential appointment: 1. Ministerial appointment (Department of Communications): 1 ...

... within the governance itself, politics will find a way to ... Presidential appointment: 1. Ministerial appointment (Department of Communications): 1 ...

| PowerPoint PPT presentation | free to view

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer - A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in ...

A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in ...

| PowerPoint PPT presentation | free to download

Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831 - Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831

Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831

| PowerPoint PPT presentation | free to download

Une - Une tude de phase II d association du lapatinib et du paclitaxel en traitement n oadjuvant chez des patientes avec un cancer du sein inflammatoire

Une tude de phase II d association du lapatinib et du paclitaxel en traitement n oadjuvant chez des patientes avec un cancer du sein inflammatoire

| PowerPoint PPT presentation | free to download

A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast Cancer Patients with Marginal Vitamin D Status - A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast ...

A Double-Blind, Randomized, Placebo-Controlled Trial of High-Dose Vitamin D Therapy on Musculoskeletal Pain and Bone Mineral Density in Anastrozole-Treated Breast ...

| PowerPoint PPT presentation | free to download

Kathy D. Miller, MD PowerPoint PPT Presentation

Kathy D. Miller, MD - Discussion Topics HER2 positive disease Growing number of options Angiogenesis Bevacizumab questions answered and rephrased Small molecule success and ...

Discussion Topics HER2 positive disease Growing number of options Angiogenesis Bevacizumab questions answered and rephrased Small molecule success and ...

| PowerPoint PPT presentation | free to download

Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005)1 Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the - ... be confirmed in the other central lab Central Laboratory HER2 % local false-positive ER % discordant IEO 14.5% of 8,037 12.1% of 9,021 Mayo Clinic 5.8% of ...

... be confirmed in the other central lab Central Laboratory HER2 % local false-positive ER % discordant IEO 14.5% of 8,037 12.1% of 9,021 Mayo Clinic 5.8% of ...

| PowerPoint PPT presentation | free to download

Analysis of Bevacizumab Therapy, Bisphosphonate Use, and Osteonecrosis of the Jaw in >3500 Patients Treated in Three Large Clinical Trials PowerPoint PPT Presentation

Analysis of Bevacizumab Therapy, Bisphosphonate Use, and Osteonecrosis of the Jaw in >3500 Patients Treated in Three Large Clinical Trials - Sporadic triple-negative breast ... + three patients with saline expanders and one with silicone implant; NS ... Reconstruction-related complications trended ...

Sporadic triple-negative breast ... + three patients with saline expanders and one with silicone implant; NS ... Reconstruction-related complications trended ...

| PowerPoint PPT presentation | free to download

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer - in Patients with HER2-Positive Advanced Breast Cancer ... 82% Neoadjuvant chemotherapy 18% 8%

in Patients with HER2-Positive Advanced Breast Cancer ... 82% Neoadjuvant chemotherapy 18% 8%

| PowerPoint PPT presentation | free to download

Comparing the Prediction of Chemotherapy Benefit in Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score - Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score

Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and RSPC, a New Measure Integrating Clinical and Pathologic Data with the Recurrence Score

| PowerPoint PPT presentation | free to download

Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( PowerPoint PPT Presentation

Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( - Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( NeoSphere )

Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ( NeoSphere )

| PowerPoint PPT presentation | free to download

Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study - Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study

Sunitinib vs Capecitabine in Patients with Previously Treated HER2-Negative Advanced Breast Cancer: A Phase III, Randomized, Open-Label Study

| PowerPoint PPT presentation | free to download

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer PowerPoint PPT Presentation

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer - Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer First Efficacy Results from the LEA ...

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer First Efficacy Results from the LEA ...

| PowerPoint PPT presentation | free to download

Cardiac Safety Results of a Phase II Trial of Adjuvant Docetaxel/Cyclophosphamide Plus Trastuzumab (Her TC) in HER2 Early Stage Breast Cancer Patients - Introduction Phase III US Oncology Research trial 9735 demonstrated that docetaxel/cyclophosphamide ... and there were no cases of clinical congestive heart failure.

Introduction Phase III US Oncology Research trial 9735 demonstrated that docetaxel/cyclophosphamide ... and there were no cases of clinical congestive heart failure.

| PowerPoint PPT presentation | free to download

Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase1 Osteonecrosis of the Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated with - Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone ... breast cancer and bone metastasis reported an 18 percent ...

Effect of Denosumab versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone ... breast cancer and bone metastasis reported an 18 percent ...

| PowerPoint PPT presentation | free to download

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1 Review of Capecitabine for the Treatment of Triple-Negative Early Breast Cancer2 - Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1

Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the FinXX Study1

| PowerPoint PPT presentation | free to download

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression - Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression

Discordance in Hormone Receptor and HER2 Status in Breast Cancer during Tumor Progression

| PowerPoint PPT presentation | free to download

Diapositiva 1 PowerPoint PPT Presentation

Diapositiva 1 - Roch H et al J Clin Oncol 2006. PACS-01: DFS in different subgroups (Forest plot analysis) ... Roch H et al J Clin Oncol 2006. ECTO Study. Gianni L, et al, ...

Roch H et al J Clin Oncol 2006. PACS-01: DFS in different subgroups (Forest plot analysis) ... Roch H et al J Clin Oncol 2006. ECTO Study. Gianni L, et al, ...

| PowerPoint PPT presentation | free to view

Adjuvant Therapy for Early Breast Cancer Subtypes Joyce O PowerPoint PPT Presentation

Adjuvant Therapy for Early Breast Cancer Subtypes Joyce O - Adjuvant Therapy for Early Breast Cancer Subtypes Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Dallas, TX

Adjuvant Therapy for Early Breast Cancer Subtypes Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Dallas, TX

| PowerPoint PPT presentation | free to download

Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged =70 Years, from the Athena Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent (LR)/ Metastatic Breast Cancer (mBC) - ... / Metastatic Breast Cancer ... no concomitant endocrine therapy No uncontrolled ... Conclusions The addition of bevacizumab to neoadjuvant therapy for patients ...

... / Metastatic Breast Cancer ... no concomitant endocrine therapy No uncontrolled ... Conclusions The addition of bevacizumab to neoadjuvant therapy for patients ...

| PowerPoint PPT presentation | free to download

313 Patients with Breast Cancer During Pregnancy PowerPoint PPT Presentation

313 Patients with Breast Cancer During Pregnancy - 313 Patients with Breast Cancer During Pregnancy Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03)

313 Patients with Breast Cancer During Pregnancy Results from a Prospective and Retrospective Registry (GBG-20/BIG02-03)

| PowerPoint PPT presentation | free to download

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up - HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up

| PowerPoint PPT presentation | free to download

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: The ZO-FAST Study 5-Year Final Follow-Up - The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

| PowerPoint PPT presentation | free to download

Phase 1b Study of Iniparib (BSI-201) Combined with Irinotecan for Treatment of Metastatic Breast Cancer1 Cell Cycle Effects of Iniparib plus Gemcitabine and Carboplatin in a Triple Negative Breast Cancer Cell Line2 Promoter CpG Methylation of BRCA1 - Sensitivity to PARP inhibitors was assessed by: Cell proliferation assays (XTT ... BRCA1 promoter methylation may be assessed as a biomarker of response in current ...

Sensitivity to PARP inhibitors was assessed by: Cell proliferation assays (XTT ... BRCA1 promoter methylation may be assessed as a biomarker of response in current ...

| PowerPoint PPT presentation | free to download

Research To Practice PowerPoint PPT Presentation

Research To Practice - Title: Research To Practice Author: Fernando G Rendina Description: www.ResearchToPractice.com/ONSBreast2014 Last modified by: Silvana Izquierdo Created Date

Title: Research To Practice Author: Fernando G Rendina Description: www.ResearchToPractice.com/ONSBreast2014 Last modified by: Silvana Izquierdo Created Date

| PowerPoint PPT presentation | free to download

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer1 The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; - The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; Exploratory Analysis ...

The Impact of Body Mass Index (BMI) on the Efficacy of Adjuvant Endocrine Therapy in Postmenopausal Hormone Sensitive Breast Cancer Patients; Exploratory Analysis ...

| PowerPoint PPT presentation | free to download

Essai AGO de phase III comparant une chimioth PowerPoint PPT Presentation

Essai AGO de phase III comparant une chimioth - Essai AGO de phase III comparant une chimioth rapie dose-dense s quentielle par ... (ETC) une chimioth rapie conventionnelle chez les patientes avec ...

Essai AGO de phase III comparant une chimioth rapie dose-dense s quentielle par ... (ETC) une chimioth rapie conventionnelle chez les patientes avec ...

| PowerPoint PPT presentation | free to view

VISION 2022 - Title: Football History Author: DannyJ Last modified by: spauw Created Date: 7/5/2013 8:17:00 PM Document presentation format: On-screen Show (4:3) Other titles

Title: Football History Author: DannyJ Last modified by: spauw Created Date: 7/5/2013 8:17:00 PM Document presentation format: On-screen Show (4:3) Other titles

| PowerPoint PPT presentation | free to download

TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1 CALGB 40302: - Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1

Versus Tamoxifen Alone in Patients with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer with Prior Exposure to Aromatase Inhibitors1

| PowerPoint PPT presentation | free to download

Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1 A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic - Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1

Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2-Positive Metastatic Breast Cancer1

| PowerPoint PPT presentation | free to download

Aucun titre de diapositive PowerPoint PPT Presentation

Aucun titre de diapositive - Les th rapeutiques cibl es dans le cancer du sein Mythes ou r alit s ? Dr. Thomas Bachelot Centre L on B rard, Lyon

Les th rapeutiques cibl es dans le cancer du sein Mythes ou r alit s ? Dr. Thomas Bachelot Centre L on B rard, Lyon

| PowerPoint PPT presentation | free to download

B27 - Over 2.5 million women living in the United States who have been diagnosed with ... paraphasing 'Bones' McCoy, Star Trek IV: The Voyage Home. Targeted Therapy ...

Over 2.5 million women living in the United States who have been diagnosed with ... paraphasing 'Bones' McCoy, Star Trek IV: The Voyage Home. Targeted Therapy ...

| PowerPoint PPT presentation | free to view

XII Jornadas Argentinas de Mastolog PowerPoint PPT Presentation

XII Jornadas Argentinas de Mastolog - What have we learned from the Randomized Trials? Ivo Olivotto BSc, MD, FRCPC. Professor Radiation oncology University of Calgary - Canada Ivo Olivotto, MD

What have we learned from the Randomized Trials? Ivo Olivotto BSc, MD, FRCPC. Professor Radiation oncology University of Calgary - Canada Ivo Olivotto, MD

| PowerPoint PPT presentation | free to download

Targeted adjuvant systemic therapy: Current status and future directions of Trastuzumab PowerPoint PPT Presentation

Targeted adjuvant systemic therapy: Current status and future directions of Trastuzumab - ... it expects an ultimate enrollment of 8,000 patients Co-amplification of c-myc and HER2: benefit of trastuzumab Co-amplification of c-myc and HER2: ...

... it expects an ultimate enrollment of 8,000 patients Co-amplification of c-myc and HER2: benefit of trastuzumab Co-amplification of c-myc and HER2: ...

| PowerPoint PPT presentation | free to view

Clinical Dilemma: PowerPoint PPT Presentation

Clinical Dilemma: - Title: PowerPoint Presentation Last modified by: jchung Document presentation format: On-screen Show Other titles: Times New Roman Verdana Marlett Arial Symbol Times ...

Title: PowerPoint Presentation Last modified by: jchung Document presentation format: On-screen Show Other titles: Times New Roman Verdana Marlett Arial Symbol Times ...

| PowerPoint PPT presentation | free to download

First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open-Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer - Dual blockage of HER2 is a valid ... from the study published by Dr Blackwell in the Journal of Clinical Oncology earlier ... Study Endpoints ...

Dual blockage of HER2 is a valid ... from the study published by Dr Blackwell in the Journal of Clinical Oncology earlier ... Study Endpoints ...

| PowerPoint PPT presentation | free to download

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study - A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study

A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study

| PowerPoint PPT presentation | free to download

Zoledronic acid in early stage breast cancer PowerPoint PPT Presentation

Zoledronic acid in early stage breast cancer - AZURE (BIG01/04): Zoledronic Acid for the Prevention of Bone Metastases in ... AZURE: Study Endpoints. Zolendronic Acid Chemotherapy is safe ...

AZURE (BIG01/04): Zoledronic Acid for the Prevention of Bone Metastases in ... AZURE: Study Endpoints. Zolendronic Acid Chemotherapy is safe ...

| PowerPoint PPT presentation | free to view

Projets de RPC PowerPoint PPT Presentation

Projets de RPC - Radioth rapie des cancers du sein pT1a, b Groupe : petites tumeur Yazid Belkac mi, David Coeffic, Paul Cottu, Florence Dalenc, William Jacot et Magali Lacroix ...

Radioth rapie des cancers du sein pT1a, b Groupe : petites tumeur Yazid Belkac mi, David Coeffic, Paul Cottu, Florence Dalenc, William Jacot et Magali Lacroix ...

| PowerPoint PPT presentation | free to download

Cancer du sein : facteurs pronostiques et pr PowerPoint PPT Presentation

Cancer du sein : facteurs pronostiques et pr - ... (r gression logistique) L effet du traitement doit tre significatif sur le crit re final (mod le de Cox) L effet du crit re interm diaire doit tre ...

... (r gression logistique) L effet du traitement doit tre significatif sur le crit re final (mod le de Cox) L effet du crit re interm diaire doit tre ...

| PowerPoint PPT presentation | free to download

Imaging to Guide Early Drug Trials PowerPoint PPT Presentation

Imaging to Guide Early Drug Trials - Most of the imaging methods presented are considered investigational ... Robert Doot. Lisa Dunnwald. Brenda Kurland. Lanell Peterson. Erin Schubert. Lavanya Sundarajan ...

Most of the imaging methods presented are considered investigational ... Robert Doot. Lisa Dunnwald. Brenda Kurland. Lanell Peterson. Erin Schubert. Lavanya Sundarajan ...

| PowerPoint PPT presentation | free to download

SABC Board Four years in Review PowerPoint PPT Presentation

SABC Board Four years in Review - Early in its tenure, the Board discussed a way of focusing the organisation on its mandate ... Magic Cellar (animation) 40 different international awards ...

Early in its tenure, the Board discussed a way of focusing the organisation on its mandate ... Magic Cellar (animation) 40 different international awards ...

| PowerPoint PPT presentation | free to download

Trial Comparison: PowerPoint PPT Presentation

Trial Comparison: - Trial Comparison: Arimidex , Tamoxifen, Alone or in Combination (ATAC) and Breast International Group (BIG) 1-98 Trial design and patient recruitment ATAC trial ...

Trial Comparison: Arimidex , Tamoxifen, Alone or in Combination (ATAC) and Breast International Group (BIG) 1-98 Trial design and patient recruitment ATAC trial ...

| PowerPoint PPT presentation | free to view

Integrated metaanalysis on 6634 patients with early breast cancer receiving neoadjuvant anthracyclin PowerPoint PPT Presentation

Integrated metaanalysis on 6634 patients with early breast cancer receiving neoadjuvant anthracyclin - von Minckwitz G, Kaufmann M, K mmel S, Fasching P, Eiermann W, Blohmer JU, Costa ... Measurable disease by ultrasound, mammography or palpation (cT4d) ...

von Minckwitz G, Kaufmann M, K mmel S, Fasching P, Eiermann W, Blohmer JU, Costa ... Measurable disease by ultrasound, mammography or palpation (cT4d) ...

| PowerPoint PPT presentation | free to view

These slides are intended to educate the scientific and medical community and keep them fully informed about continuing progress, as is their right, stipulated by the IFPMA code. However, in some cases, the data may refer to medicines and/or indications - These s are intended to educate the scientific and medical community and keep them fully informed about continuing progress, as is their right, stipulated by the ...

These s are intended to educate the scientific and medical community and keep them fully informed about continuing progress, as is their right, stipulated by the ...

| PowerPoint PPT presentation | free to download

IRM PREOPERATOIRE Comment en tenir compte - IRM PREOPERATOIRE Comment en tenir compte

IRM PREOPERATOIRE Comment en tenir compte

| PowerPoint PPT presentation | free to view

La chemioterapia adiuvante PowerPoint PPT Presentation

La chemioterapia adiuvante - La chemioterapia adiuvante Lucia Del Mastro Istituto Naz. per la Ricerca sul Cancro - Genova Roma 18 Febbraio 2005 Adjuvant chemotherapy The present Anthracyclines ...

La chemioterapia adiuvante Lucia Del Mastro Istituto Naz. per la Ricerca sul Cancro - Genova Roma 18 Febbraio 2005 Adjuvant chemotherapy The present Anthracyclines ...

| PowerPoint PPT presentation | free to view

Diapositiva 1 - ... routine level I and level II axillary lymph node dissection (ALND) has been performed for breast cancer patients, except for those with noninvasive breast cancer.

... routine level I and level II axillary lymph node dissection (ALND) has been performed for breast cancer patients, except for those with noninvasive breast cancer.

| PowerPoint PPT presentation | free to view

Presentation to the Parliamentary Portfolio Committee on Home Affairs PowerPoint PPT Presentation

Presentation to the Parliamentary Portfolio Committee on Home Affairs - ... DECENCY TASTE AND DECENCY TASTE AND DECENCY AUDIENCE ADVISORIES SCREENING OF FILMS THE WATERSHED THE WATERSHED AND CHILDREN ... impact of violent or ... cartoons ...

... DECENCY TASTE AND DECENCY TASTE AND DECENCY AUDIENCE ADVISORIES SCREENING OF FILMS THE WATERSHED THE WATERSHED AND CHILDREN ... impact of violent or ... cartoons ...

| PowerPoint PPT presentation | free to download

Tubulin Inhibition in Breast Cancer: A Therapeutic Target Critical to Improving Outcomes PowerPoint PPT Presentation

Tubulin Inhibition in Breast Cancer: A Therapeutic Target Critical to Improving Outcomes - Paclitaxel and bevacizumab Capecitabine Capecitabine and docetaxel Gemcitabine and paclitaxel nab-paclitaxel Case #2 (cont.) The patient receives capecitabine as a ...

Paclitaxel and bevacizumab Capecitabine Capecitabine and docetaxel Gemcitabine and paclitaxel nab-paclitaxel Case #2 (cont.) The patient receives capecitabine as a ...

| PowerPoint PPT presentation | free to download

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer: Resurrection of Survival Endpoint PowerPoint PPT Presentation

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer: Resurrection of Survival Endpoint - Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer: Resurrection of Survival Endpoint Rita Mehta, MD Associate Clinical Professor

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer: Resurrection of Survival Endpoint Rita Mehta, MD Associate Clinical Professor

| PowerPoint PPT presentation | free to view

Personalized Medicine PowerPoint PPT Presentation

Personalized Medicine - May cause disease like cancer if occur in genes controlling cell growth, etc ... Therefore, there are many possible combinations of changes that can cause cancer ...

May cause disease like cancer if occur in genes controlling cell growth, etc ... Therefore, there are many possible combinations of changes that can cause cancer ...

| PowerPoint PPT presentation | free to view

Bisphosphonate treatment of metastatic bone disease in breast cancer NEW DATA PowerPoint PPT Presentation

Bisphosphonate treatment of metastatic bone disease in breast cancer NEW DATA - Bisphosphonate treatment of metastatic bone disease in breast cancer ... women or castrated men) BAP low ( 146 U/L: corresponds to ' upper limit of. normal ' ...

Bisphosphonate treatment of metastatic bone disease in breast cancer ... women or castrated men) BAP low ( 146 U/L: corresponds to ' upper limit of. normal ' ...

| PowerPoint PPT presentation | free to view

Pharmacogenomics, personalized medicine and the drug development process' PowerPoint PPT Presentation

Pharmacogenomics, personalized medicine and the drug development process' - Pharmacogenomics, personalized medicine and the drug development process. ... Based on analysis of Martingale residuals, create non-linear (threshold) functional forms ...

Pharmacogenomics, personalized medicine and the drug development process. ... Based on analysis of Martingale residuals, create non-linear (threshold) functional forms ...

| PowerPoint PPT presentation | free to view

Sabcs PowerPoint PPT Presentations